Preconditioning of primary human endothelial cells with inflammatory mediators alters the “set point” of the cell by Wada, Youichiro et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Faculty Publications from the Department of
Electrical and Computer Engineering Electrical & Computer Engineering, Department of
2005
Preconditioning of primary human endothelial
cells with inflammatory mediators alters the “set
point” of the cell
Youichiro Wada
Beth Israel Deaconess Medical Center
Hasan H. Otu
Beth Israel Deaconess Medical Center, hotu2@unl.edu
Shengqian Wu
Beth Israel Deaconess Medical Center
Md. Ruhul Abid
Beth Israel Deaconess Medical Center
Hitomi Okada
Beth Israel Deaconess Medical Center
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/electricalengineeringfacpub
Part of the Computer Engineering Commons, and the Electrical and Computer Engineering
Commons
This Article is brought to you for free and open access by the Electrical & Computer Engineering, Department of at DigitalCommons@University of
Nebraska - Lincoln. It has been accepted for inclusion in Faculty Publications from the Department of Electrical and Computer Engineering by an
authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Wada, Youichiro; Otu, Hasan H.; Wu, Shengqian; Abid, Md. Ruhul; Okada, Hitomi; Libermann, Towia; Kodama, Tatsuhiko; Shih,
Shu-Ching; Minami, Takashi; and Aird, William C., "Preconditioning of primary human endothelial cells with inflammatory
mediators alters the “set point” of the cell" (2005). Faculty Publications from the Department of Electrical and Computer Engineering. 433.
http://digitalcommons.unl.edu/electricalengineeringfacpub/433
Authors
Youichiro Wada, Hasan H. Otu, Shengqian Wu, Md. Ruhul Abid, Hitomi Okada, Towia Libermann,
Tatsuhiko Kodama, Shu-Ching Shih, Takashi Minami, and William C. Aird
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/
electricalengineeringfacpub/433
Preconditioning of primary human endothelial cells with 
inflammatory mediators alters the “set point” of the cell
Youichiro Wada*, Hasan Otu*, Shengqian Wu*, Md. Ruhul Abid*, Hitomi Okada*, Towia 
Libermann*, Tatsuhiko Kodama†, Shu-Ching Shih*,‡, Takashi Minami†, and William C. Aird*
*The Center for Vascular Biology Research and Division of Molecular and Vascular Medicine, 
Beth Israel Deaconess Medical Center, Boston, MA
‡Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA
†The Research Center for Advanced Science and Technology, the University of Tokyo, Tokyo, 
Japan
Abstract
Endothelial cells are highly sensitive to changes in the extracellular milieu. Sepsis results in 
activation of inflammatory and coagulation pathways. We hypothesized that sepsis-associated 
mediators may alter the response capacity (so-called “set point”) of endothelial cells. Human 
umbilical vein endothelial cells (HUVEC) were preincubated in the presence or absence of tumor 
necrosis factor (TNF)-α, lipopolysaccharide (LPS), hypoxia, hyperthermia, and/or high glucose; 
treated with or without thrombin for 4 h; and then processed for RNase protection assays of 
selected activation markers. Priming with TNF-α and LPS significantly inhibited thrombin-
mediated induction of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, tissue 
factor, and E-selectin, but not platelet-derived growth factor-A or CD44. In electrophoretic 
mobility shift assays, thrombin-treated HUVEC demonstrated inducible binding of p65 NF-κB, an 
effect that was significantly blunted by pretreatment of cells with TNF-α and LPS. Consistent with 
these results, TNF-α and LPS attenuated the effect of thrombin on IκB phosphorylation, total 
cytoplasmic IκB, and nuclear translocation of p65 NF-κB. The inhibitory effect of TNF-α on 
thrombin signaling persisted for up to 24 h following removal of the cytokine. Taken together, 
these data suggest that inflammatory mediators prime endothelial cells to modulate subsequent 
thrombin response.
Keywords
endothelium; NF-κB; sepsis; thrombin; HUVEC
The endothelium participates in many homeostatic functions, including the maintenance of 
blood fluidity, the regulation of leukocyte adhesion and transmigration, the production of 
inflammatory mediators, and the control of permeability (reviewed in ref 1).
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Sepsis, which is defined as systemic inflammatory response to infection, involves the 
activation of both inflammatory and coagulation pathways. The host response is complex 
and involves a nonlinear array of cells (monocytes/macrophages, neutrophils, platelets, and 
endothelial cells) and soluble mediators (cytokines, chemokines, compliment, growth 
factors; changes in temperature, glucose, pH, and oxygen). Increasing evidence points to the 
endothelium as both victim and perpetrator of the sepsis cascade (reviewed in ref 2). For 
example, previous studies have demonstrated structural changes and apoptosis of endothelial 
cells in sepsis. Moreover, a common thread in successful treatments of severe sepsis is their 
capacity to attenuate endothelial cell dysfunction (3). Whether or not the endothelium 
represents a valuable therapeutic target will depend on an improved understanding of this 
organ in health and disease.
Many studies in endothelial cell biology focus on the effect of one or another extracellular 
mediator on unperturbed monolayers of cultured cells. As one example, thrombin has been 
shown to disrupt barrier function, alter cell shape, activate myriad signaling pathways and 
transcriptional networks, induce leukocyte adhesion, and shift endothelial-derived 
hemostatic balance (reviewed in ref 4). However, the extent to which these results may be 
extrapolated in vivo is not clear. In the context of the intact organism, the endothelium is 
exposed to many biomechanical and biochemical factors that vary in both space and time. In 
patients with severe sepsis, the endothelial microenvironment undergoes significant changes, 
including increased circulating levels of cytokines and chemokines, activation of serine 
proteases, hyperglycemia, hyperthermia, acidosis, and/or hypoxia.
Given the remarkable capacity of the endothelium to integrate extracellular signals, we 
hypothesized that a change in microenvironment—as occurs in sepsis—is likely to alter the 
cell’s subsequent capacity to respond to one or another agonist. To test this hypothesis, we 
exposed primary human endothelial cells to a variety of preconditioning regimens 
commonly associated with sepsis (including hyperthermia, hypoxia, high glucose, tumor 
necrosis factor [TNF]-α, and lipopolysaccharide [LPS]), and then incubated the cells with 
thrombin. Using gene transcription as our read out, we demonstrate that the net signal input 
is indeed an important determinant of the cell’s subsequent response.
MATERIALS AND METHODS
Cell culture
Human umbilical vein endothelial cells (HUVEC) and human coronary artery endothelial 
cells (HCAEC) were purchased from Clonetics (Hopkinton, MA) and grown in endothelial 
growth medium-2-MV (EGM-2-MV; Clonetics). After reaching confluence, cells were 
cultivated in serum-starved medium (EBM-2 containing 0.5% FBS) for 6 h, and exposed to 
one or more of the following conditions for 14 h: 1) 4.5 g/L (25 mM) glucose, 2) 39.5°C 
using temperaturecontrolled incubator, 3) 1% O2 using an airtight Plexiglass chamber with 
an atmosphere of 5% CO2/95% N2 at 37°C, 4) 10 µg/ml LPS (Sigma, St. Louis, MO), and/or 
5) 20 ng/ml TNF-α (Invitrogen, Carlsbad, CA). Following preconditioning, the cells were 
incubated in fresh serum-starved medium in the presence or absence of 1.5 U/ml thrombin 
(Calbiochem, La Jolla, CA) for the times specified. In “washout” experiments, 
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preconditioning medium (containing TNF-α) was replaced with fresh medium for 24 h 
before thrombin treatment. All experiments were carried out with cells at passage 6 or less.
RNase protection assays
Reverse transcriptase-polymerase chain reaction (RT-PCR) fragments were generated using 
SuperScript First-Strand Synthesis system (Invitrogen) from human genomic DNA solution 
(Roche, Basel, Switzerland) and subcloned into the pCRII vector (Invitrogen). After 
verification of the cDNA inserts, plasmids were amplified and purified using Qiagen plasmid 
Midi Kit (Qiagen, Valencia, CA). The plasmids were linearized and used as in vitro 
transcription templates. The cDNA plasmid template for β-actin was purchased from 
Ambion (Austin, TX). Following preconditioning and thrombin stimulation, cells were 
harvested for RNA using TRIzol reagent (Invitrogen). Total RNA was extracted according to 
the manufacturer’s instructions. α- [32P] UTP-labeled riboprobes were synthesized from the 
cDNA templates, using either T3 or T7 RNA polymerase (Ambion) and subsequently gel 
purified. RNase protection assays were carried out using the RPA III kit (Ambion) as 
described previously (5).
Quantitative real-time PCR
Total RNA was prepared using the RNeasy RNA extraction kit with DNase I treatment 
following the manufacturer’s instructions (Qiagen). To generate cDNA, total RNA (100 ng) 
from each of triplicate samples was mixed and converted into cDNA using random primers 
and SuperscriptIII reverse transcriptase (Invitrogen). All cDNA samples were aliquoted and 
stored at −80°C. Primers were designed using the Primer Express oligo design software 
(Applied BioSystems, Foster City, CA) and synthesized by Genemed Synthesis (South San 
Francisco, CA). All primer sets were subjected to rigorous database searches to identify 
potential conflicting transcript matches to pseudogenes or homologous domains within 
related genes. Amplicons generated from the primer set were analyzed for melting point 
temperatures using the first derivative primer melting curve software supplied by Applied 
BioSystems. The sequences of all real-time PCR primers used in this paper are listed in 
Table 1. The SYBR Green I assay and the ABI Prism 7700 Sequence Detection System were 
used for detecting real-time PCR products from the reverse-transcribed cDNA samples, as 
described previously (6). β-Actin, which exhibits a constant expression level across all of the 
HUVEC samples in comparison with 18S rRNA, was used as the normalizer. PCR reactions 
for each sample were performed in duplicate, and copy numbers were measured as described 
previously (6). The level of target gene expression was normalized against the β-actin 
expression in each sample and the data presented as mRNA copies per 106 β-actin copies.
Oligonucleotide microarray analysis of gene expression
The transcriptional profile of control or thrombin-treated HUVEC preconditioned with or 
without LPS or TNF-α was characterized by oligonucleotide microarray analysis of 
HUVEC by using the human U133A Affymetrix GeneChip, according to previously 
described protocols for total RNA extraction and purification, cDNA synthesis, in vitro 
transcription reaction for production of biotin-labeled cRNA, hybridization of cRNA with 
U133A Affymetrix gene chips, scanning of image output files, analysis of gene expression 
data, and hierarchical and functional clustering algorithms (7). The scanned array images 
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were analyzed by dChip (8). In the dChip analysis, a smoothing spline normalization method 
was applied before obtaining model-based gene expression indices, also known as signal 
values. There were no outliers identified by dChip, so all samples were carried on for 
subsequent analysis. When comparing two (groups of) samples to identify the genes 
enriched in a given phenotype, we used the lower confidence bound (LCB) of the fold 
change (FC) between the experiment and the baseline. If the 90% LCB of the FC between 
the experiment and the baseline was >1.2, the corresponding gene was considered to be 
differentially expressed. An LCB >1.2 typically corresponds with an “actual” fold change of 
at least 3 in gene expression. GOTree Machine (GOTM) was used to identify Gene Ontology 
categories for the input gene set (9).
Electrophoretic mobility shift assays
Nuclear extracts were prepared using Nuclear Extract Kit from Active Motif (Carlsbad, CA). 
Double-stranded oligonucleotides spanning the tandem NF-κB sites in the VCAM-1 
promoter (5′-TGCCCTGGGTTTCCCCTTGAAGGGATTTCCCTCCGCCTC-3′) were 
labeled with [α-32P] dCTP and Klenow fragment, purified by spun column (Amersham 
Pharmacia), and incubated with nuclear extracts as described previously (10). To test the 
effect of antibody on DNA-protein binding, nuclear extracts were preincubated with 
antibody to p65 (Santa Cruz Biotechnology, Santa Cruz, CA) for 30 min at room 
temperature. In competition experiments, nuclear extracts were preincubated with 50-fold 
molar excess of unlabeled wild-type or mutant oligonucleotides (5′-
TGCCCTGCCTTTCCGGTTGAAGCCATTTCGGTCCGCC-3′) for 20 min at room 
temperature, and added to the reaction mixture as described previously (11).
Immunolocalization of p65 NF-κB
For immunolocalization studies, HUVEC or HCAEC were plated onto eight-well chamber 
slides (Lab-Tek, Christchurch, New Zealand) at a density of 20,000 cells/well. The cells 
were grown in EGM-2 MV medium for 48 h and fixed in 4% paraformaldehyde at room 
temperature for 10 min, washed with PBS, and subsequently incubated with primary anti-
p65 antibody (Santa Cruz Biotechnology; 1: 100 dilution) for 30 min. Following extensive 
washes in PBS, the cells were incubated with a FITC-labeled secondary antibody (1:100 
dilution) for 30 min. Following additional PBS washes, the slides were mounted in Prolong 
Gold antifade reagent (Molecular Probes, Eugene, OR) and viewed with confocal 
fluorescence microscopy. TO-PRO-3 (Molecular Probes) was used for nuclear 
colocalization.
Assays for total and phospho-IκBα
HUVEC were preconditioned with LPS or TNF-α and then treated with or without 
thrombin. After thrombin addition (time 0), cytoplasmic fraction was prepared at 15, 30, 45, 
60, 120, 180 and 240 min using protein extract kit from Active Motif. Western blots were 
carried out as described previously (12). In each lane of 10% gel, 120 µg of protein was 
applied. The specific antibodies against IκBα and phospho-IκBα were purchased from Cell 
Signaling (Beverly, MA). Western blots were carried out in triplicate, using independent 
preparations of cytoplasmic extracts. The signals were quantified with NIH Image, and 
statistical analyses were carried out using Student’s t test.
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RESULTS
The effect of preconditioning on thrombin-mediated gene expression in HUVEC
To determine the effect of different sepsis-like preconditioning regimes on thrombin-
mediated gene expression, we pretreated HUVEC for 14 h in the presence or absence of high 
glucose, TNF-α, and/or LPS, and then treated with or without 1.5 U/ml thrombin for 4 h. 
Alternatively, HUVEC were grown under hypoxic or hyperthermic conditions before 
thrombin treatment. Cells were harvested for RNA and assayed for gene expression by 
RNase protection assay. In the absence of preconditioning, thrombin induced the expression 
of TF, ICAM-1, u-PA, COX-2, E-selectin, VCAM-1, and PDGF-A, but not CD44 (Fig. 1A, 
1B; for quantitation, see Supplemental Fig. 1). In the absence of thrombin treatment, 
preconditioning with TNF-α, and to a lesser extent LPS, increased basal expression of 
several target genes, including ICAM-1, u-PA, CD44, and COX-2. The effect of LPS was 
accentuated by concomitant hypoxia.
The various preconditioning regimens had different effects on thrombin-mediated gene 
expression (Fig. 1A, 1B; for quantitation, see Supplemental Fig. 1). Pretreatment with TNF-
α or LPS significantly reduced thrombin stimulation of TF, ICAM-1, u-PA, E-selectin, and 
VCAM-1 but had little or no effect on PDGF-A. In contrast, high glucose, hyperthermia, or 
hypoxia alone had little or no effect on thrombin response. In cells exposed to a combination 
of high glucose and hypoxia, there was a trend toward super-induction of thrombin-
responsive genes. Interestingly, the data suggest that TNF-α or LPS sensitizes CD44 and 
COX-2 to the effect of thrombin. In contrast to these sepsis-like regimens, the addition of 
vascular endothelial growth factor, hepatocyte growth factor, or insulin-like growth factor 
had no significant effect on thrombin-induced VCAM-1 expression (Supplemental Fig. 2).
To further quantify the above findings, we used a novel TaqMan-based protocol for 
calculating mRNA copy number per cell (Fig. 2A, 2B). Consistent with the results of RNase 
protection, TNF-α attenuated subsequent thrombin-mediated induction of TF (from 75-fold 
to 10-fold), ICAM-1 (from 22-fold to 1.3-fold), VCAM-1 (from 70-fold to 1.2-fold), E-
selectin (from 142- fold to 2.9-fold), and u-PA (from 2.9-fold to 1.2-fold). TNF-α had no 
effect on thrombin stimulation of CD44 and PDGF-A. In contrast to the results of RNase 
protection assays, TNF-α preconditioning did inhibit thrombin induction of COX-2 (from 
10.6-fold to 5-fold). Finally, the same pattern of inhibition was observed with TNF-α doses 
as low as 0.2 ng/ml (data not shown).
DNA microarray analyses of thrombin-responsive gene expression in TNF-α- or LPS-
preconditioned HUVEC
Next, we used DNA microarrays to conduct a global survey of thrombin-responsive genes in 
preconditioned endothelial cells. Pretreatment with TNF-α alone for 14 h resulted in the 
induction of 612 genes and repression of 565 transcripts. Pretreatment with LPS alone for 14 
h resulted in induction and suppression of 70 and 48 genes, respectively. In the absence of 
preconditioning, thrombin treatment for 2 h resulted in induction and suppression of 323 and 
61 genes, respectively. These latter results are consistent with recent published data from our 
group (13). Pretreatment of HUVEC with TNF-α or LPS had a significant impact on 
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subsequent thrombin response. Specifically, TNF-α inhibited thrombin-mediated induction 
of 105 genes (Fig. 3A, group b and c), and resulted in super-induction of 3 genes (Fig. 3A, 
group e and f) (Supplemental Fig. 3). The remainder of the thrombin responsive genes were 
unaffected by TNF-α preconditioning (215 genes out of 323 genes). LPS inhibited 
thrombin-mediated induction of 34 genes (Fig. 3A, group a and b), and resulted in super-
induction of 3 thrombin-responsive genes (Fig. 3A, group d and e) (Supplemental Fig. 3). 
The remainder of the thrombin-responsive genes was unchanged by LPS preconditioning 
(286 out of 323 genes).
TNF-α and LPS inhibited thrombin stimulation of 16 common genes (Fig. 3A, group b; Fig. 
3B). Among these genes are Down syndrome critical region (DSCR)-1, which we recently 
reported to be a thrombin-responsive autoinhibitory factor (14), numerous genes involved 
TNF-α signaling, syndecan 4, and caveolin 2. Consistent with the results of the RNase 
protection assays, TNF-α and LPS inhibited thrombin stimulation of E-selectin, ICAM-1, 
and VCAM-1, but not PDGF-A or COX-2.
TNF-α and LPS inhibit DNA binding of p65 NF-κB
We were interested in determining the mechanism(s) by which pretreatment of HUVEC with 
TNF-α or LPS altered subsequent thrombin response. NF-κB has been previously 
implicated in the transcriptional regulation of many of the thrombin-responsive genes that 
were attenuated by preconditioning with TNF-α or LPS. In duplicate DNA microarray 
studies, we found that overexpression of a degradation-resistant constitutively active IκBα 
(IκB S32A/S36A) inhibited thrombin-mediated induction of ICAM-1, VCAM-1, E-selectin, 
and u-PA, but not CD44, COX-2, and PDGF-B (data not shown). Thus, we focused on the 
role for this transcription factor in mediating the inhibitory effect of preconditioning on 
thrombin response. To that end, EMSA were carried out using a radiolabeled double-
stranded oligonucleotide probe containing the two adjacent VCAM-1 NF-κB consensus 
motifs, and nuclear extracts from HUVEC that had been pretreated with TNF-α or LPS and 
then incubated in the absence or presence of thrombin. In some cases, supershifting anti-p65 
NF-κB antibodies were added to the reaction mixture to assay for p65 NF-κB binding. As 
shown in Fig. 4A and 4B, the addition of thrombin alone resulted in a fourfold increase in 
total NF-κB and p65 NF-κB binding. Preconditioning with TNF-α alone resulted in 
increased basal DNA binding of total NF-κB (2.3-fold) and p65 NF-κB (2.2-fold), whereas 
the effect of LPS was relatively small and limited to total NF-κB (1.3-fold) (Fig. 4A, 4B). 
More importantly, preconditioning with TNF-α and, to a lesser extent, LPS significantly 
inhibited thrombin-mediated induction of NF-κB binding. These data were confirmed using 
ELISA-based assays for p65 NF-κB binding activity (data not shown).
TNF-α inhibits thrombin stimulation of phospho-IκB and nuclear translocation of p65 NF-
κB
We next wished to study the effect of TNF-α and LPS preconditioning on the IκB-NF-κB 
signaling axis. Exposure of HUVEC to thrombin alone resulted in time-dependent increase 
in IκB phosphorylation and reduction in total cytoplasmic IκB, with maximal changes 
occurring at 180 min and 120 min, respectively (Fig. 5A, 5B). Pretreatment with TNF-α 
(and to a lesser extent LPS) resulted in increased basal levels of phospho-IκB. Importantly, 
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both agonists blocked the effect of thrombin on total and phospho-IκB. In the case of TNF-
α preconditioning, levels of phospho-IκB actually decreased in the thrombin-treated cells, 
an effect that is likely explained by the removal of TNF-α from the medium.
Based on the results of the EMSA and the Western blots, we predicted that preconditioning 
with TNF-α or LPS would inhibit nuclear translocation of p65 NF-κB. To test this 
hypothesis, we carried out immunofluorescent studies in primary endothelial cells. HUVEC 
and HCAEC treated with thrombin for 2 h demonstrated significant nuclear translocation of 
p65 NF-κB (compare Fig. 6B and 6C). In endothelial cells preconditioned with TNF-α for 
14 h, p65 NF-κB was localized predominantly in the nucleus (compare Fig. 6A and 6G), 
whereas LPS-primed endothelial cells revealed partial nuclear translocation of p65 NF-κB 
(compare Fig. 6A and 6D). Following 14 h of preconditioning, TNF-α or LPS was removed 
and the cells were incubated for 2 h in fresh medium in the absence (control) or presence of 
thrombin. In the absence of thrombin, a majority of the p65 NF-κB was localized in the 
cytoplasm after 2 h (Fig. 6F and 6I). A similar pattern of cytoplasmic accumulation was 
observed in the presence of thrombin (Fig. 6E and 6H). These results suggest that 
preconditioning with TNF-α or LPS significantly blocks the capacity of thrombin to induce 
nuclear translocation of p65 NF-κB.
Effect of TNF-α and LPS preconditioning on thrombin signaling is sustained after removal 
of cytokine from the culture medium
Following a 24 h washout period, in which TNF-α-preconditioned cells were allowed to 
recover in fresh medium for 24 h before addition of thrombin, the copy number of each 
target gene approached baseline levels (e.g., in the absence of any preconditioning) (Fig. 7A, 
7B). However, the attenuating effect of TNF-α on thrombin-mediated gene induction was 
still evident, with TF reduced from 65-fold to 6.3-fold; ICAM-1 from 17.6-fold to 1.3-fold; 
VCAM-1 from 69-fold to 5.8-fold; E-selectin from 164-fold to 29-fold; and u-PA from 2.0-
fold to 1.4-fold (Fig. 7B). Induction of COX-2 was reduced from 15-fold to 9-fold. Again, 
TNF-α had no influence on thrombin’s effect on CD44 or PDGF-A. The inhibitory effect of 
TNF-α on thrombin-mediated NF-κB binding, IκB phosphorylation, and IκB degradation 
persisted following the 24 h washout period (data not shown).
Preconditioning with thrombin has little effect on LPS and TNF-α signaling
We next asked whether there is a reciprocal effect of thrombin preconditioning on LPS and 
TNF-α-mediated gene expression. To that end, HUVEC were preconditioned overnight with 
1.5 U/ml thrombin and subsequently exposed to thrombin, LPS, or TNF-α. As shown in Fig. 
8A and 8B, preconditioning with thrombin attenuated subsequent thrombin-mediated 
induction of TF, ICAM-1, E-selectin, and VCAM-1. However, no such effect was seen with 
PDGF-A, u-PA, or COX-2, arguing against simple consumption or desensitization of PAR-1 
(for quantitation, see Supplemental Fig. 4). In contrast to the effects on subsequent thrombin 
response, preconditioning with thrombin had no effects on TNF-α- or LPS-mediated 
induction of TF, ICAM-1, E-selectin, or VCAM-1. These results suggest that a change in set 
point and its effect on subsequent signaling depends on the nature of the preconditioning 
agent, the agonist being tested and the identity of the target gene.
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DISCUSSION
Thrombin is a multifunctional serine protease that activates protease-activated receptors 
(PAR) expressed on the surface of multiple cell types, including endothelial cells. PAR-1 is 
the predominant thrombin receptor on endothelial cells. Activation of PAR-1 leads to a 
series of posttranscriptional and transcriptional changes, which ultimately contribute to an 
alteration of structural and/or functional phenotype (reviewed in ref 4). Thrombin has been 
shown to induce the activity of many transcription factors, including NF-κB, AP1, Egr-1, 
and the forkhead family of proteins (4). These transcriptional networks, in turn, modulate the 
expression of many target genes, including cell adhesion molecules, procoagulants, and 
inflammatory mediators (4).
In the current study, we have shown that inflammatory mediators prime endothelial cells to 
modulate subsequent thrombin response. TNF-α and LPS alone had the greatest effect on 
thrombin-mediated gene regulation. An important finding was that for a given regimen, 
preconditioning inhibited thrombin response of some genes and accentuated the response of 
others. Moreover, each agonist demonstrated overlapping yet distinct effects on thrombin-
responsive gene expression.
Our data point to the importance of NF-κB in mediating the inhibitory effects of 
preconditioning. We demonstrated that LPS and TNF-α each impair thrombin-mediated 
phosphorylation of IκB, degradation of cytoplasmic IκB, nuclear mobilization, and DNA 
binding of p65 NF-κB. The preconditioned endothelial cell is thus hyporesponsive to NF-
κB-dependent thrombin signaling. It is interesting to speculate that the priming regimen 
directly interferes with IκB/NF-κB or with an upstream signal intermediate. One attractive 
hypothesis is that LPS and TNF-α deplete or inhibit PKC-δ, which is necessary for 
mediating thrombin stimulation of ICAM-1 and VCAM-1 (11, 15), and potentially other 
downstream target genes.
We cannot exclude a role for other signal intermediates and/or transcription factors in 
mediating the effects of preconditioning with inflammatory mediators. For example, 
preconditioning with TNF-α also inhibited thrombin induction of NF-AT and DSCR-1 (data 
not shown). Such an effect would be predicted to contribute to the attenuation of thrombin-
induced expression of E-selectin, VCAM-1, ICAM-1, and TF. Still other mechanisms may 
be involved in mediating the positive effects of TNF-α on thrombin-induced COX-2 and 
CD44, as well as the positive effects of high glucose combined with hypoxia on several 
thrombin-responsive target genes.
In recent years, a number of other studies have demonstrated the potential for 
preconditioning regimens to sensitize or desensitize endothelial cells to other agonists. For 
example, the term “ischemic preconditioning” describes the cytoprotective effect of 
ischemia-reperfusion or hypoxia on tissues and/or endothelial cells (16). “Transplantation 
accommodation” occurs when xenoreactive or alloreactive antibodies induce resistance of 
the endothelium to humoral rejection (17). Repeated challenge of endothelial cells with LPS 
results in temporary insensitivity to subsequent LPS challenge, a process that has been 
termed “endotoxin tolerance.” Other preconditioning regimens that have been demonstrated 
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to alter endothelial cell signaling include hypoxia (18), heat shock (19), and IGF-1 (20). 
Together with our data, these studies support the notion that the history of signal input is a 
critical determinant of subsequent cell behavior. This is likely to be true under both normal 
and pathophysiological conditions. At any given point in time, each endothelial cell in the 
human body has been preconditioned by its past exposure to diverse biomechanical and 
biochemical forces. The term “set point” refers to the functional sequelae of that input 
history.
Collectively, these data suggest that the endothelium may be therapeutically primed in such 
a way as to reduce subsequent activation. A total of five phase 3 clinical trials have 
demonstrated improved survival in critically ill patients or patients with severe sepsis. These 
include the use of low tidal volume ventilation (21), activated protein C (22), low dose 
glucocorticoids (23), intensive insulin therapy (24), and early goal-directed therapy (25). It is 
possible that each of these regimens exerts its benefit through a protective effect on the 
endothelium. For example, activated rhAPC may attenuate the response of endothelial cells 
to inflammatory mediators, early goal-directed therapy may result in favorable 
hemodynamics at the level of the endothelium, and intensive insulin therapy reverses any 
deleterious effect of hyperglycemia on endothelial responses. The link between therapeutic 
efficacy and alteration of endothelial set point is hypothetical and will require further study 
(26).
Finally, our results have important implications for studying endothelial cells in vitro. In 
most instances, cultured cells are incubated with agonist at time 0, and assayed at some later 
point for mRNA, protein, and/or function. Typically, the pretreatment conditions are 
standardized (e.g., serum-starved medium). We have shown that simple changes in the 
starting conditions result in complex shifts in subsequent behavior. Moreover, these changes 
may persist even after removal of the preconditioning regimen. Thus, when designing 
studies of cultured endothelial cells, it is important to take into consideration (and where 
necessary, modulate) the pretreatment conditions.
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Figure 1. 
The effect of preconditioning on thrombin-mediated expression of candidate genes in 
endothelial cells. A, B) HUVEC were serum-starved for 6 h, preconditioned with high 
glucose, high temperature, low oxygen tension, TNF-α, and LPS alone or in combination for 
14 h, and then treated with or without 1.5 U/ml thrombin for 4 h. RNase protection assays 
were carried out for expression of tissue factor (TF), platelet-derived growth factor (PDGF)-
A, intercellular adhesion molecule (ICAM)-1, urokinase type plasminogen activator (u-PA), 
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CD44, prostaglandin synthase 2 (COX-2), E-selectin, vascular cell adhesion molecule 
(VCAM)-1, and β-actin as described in Materials and Methods.
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Figure 2. 
Validation of RNase protection assays using quantitative real-time PCR. Real-time PCR 
products were detected from the reverse-transcribed cDNA samples using SYBR Green I 
assay and the ABI Prism 7700 Sequence Detection System. The level of target gene 
expression was normalized against the β-actin expression in each sample, and the data are 
presented as mRNA copies per 106 β-actin copies. A) Expression levels in 
nonpreconditioned HUVEC treated in the absence (NS) or presence (THR) of thrombin for 4 
h. B) Expression levels in HUVEC preconditioned with TNF-α for 14 h and treated in the 
absence (NS) or presence (THR) of thrombin for 4 h. NS, no stimulation; THR, thrombin 
stimulation; NP, no preconditioning.
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Figure 3. 
DNA microarray analyses of thrombin-responsive gene expression in TNF-α or LPS 
preconditioned endothelial cells. A) Venn diagram of thrombin-stimulated genes whose 
induction was inhibited by preconditioning with LPS (a), TNF-α (c), or both (b); or up-
regulated by preconditioning with LPS (d), TNF-α (f), or both (e). B) Colormap of signal 
values for the genes in group B. Gene names and Affymetrix IDs are shown next to each 
row. For each gene, red and blue indicate high and low expression, respectively. For visual 
purposes, the signal values are normalized to the range [−3,3].
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Figure 4. 
TNF-α and LPS inhibit DNA binding of p65 NF-κB in endothelial cells. A) Representative 
electrophoretic mobility shift assay (EMSA) performed with 32 P-labeled NF-κB probe and 
12 µg of nuclear extract from control (lanes 1, 3, 5, 9, 11, 13) or thrombin-treated (lanes 2, 4, 
6–8, 10, 12, 14) HUVEC preconditioned in the absence (lanes 1, 2, 7, 8, 9, 10) or presence 
of LPS (lanes 3, 4, 11, and 12) and TNF-α (lanes 5, 6, 13, and 14). To identify specific 
DNA-protein complexes, nuclear extracts were incubated with wild-type probe (lane 7) or 
mutated probe (lane 8). The arrow indicates specific NF-κB DNA-protein complex. For 
Wada et al. Page 16
FASEB J. Author manuscript; available in PMC 2017 April 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
supershift analysis, thrombin-treated HUVEC were incubated with antibody against p65 NF-
κB (lanes 9–14). The arrowhead indicates the super-shifted complex. B) Quantification of 
total NF-κB and p65 NF-κB binding. The results show mean ± SE of the specific signal, 
relative to nonpreconditioned and nonstimulated (NPNS), obtained from three independent 
experiments. *P < 0.05. NP; no preconditioning; NS, no thrombin stimulation; LPS, LPS 
preconditioning; TNF, TNF-α preconditioning; THR; thrombin stimulation.
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Figure 5. 
TNF-α and LPS inhibit thrombin stimulation of phospho-IκB and p65 NF-κB in endothelial 
cells. A) Representative Western blot of HUVEC preconditioned with LPS or TNF-α, and 
then stimulated in the absence or presence of 1.5 U/ml thrombin. After thrombin addition 
(time 0), cytoplasmic fraction was prepared at 15, 30, 45, 60, 120, 180, and 240 min, and 
Western blots were performed on the same membrane using specific antibodies against 
IκBα, phospho-IκBα, and β-actin. In each lane, 120 µg of protein was loaded onto a 10% 
gel. B) Relative density of both phospho-IκBα and total IκBα at time 0 was adjusted to 100, 
Wada et al. Page 19
FASEB J. Author manuscript; available in PMC 2017 April 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and relative values of all other bands are plotted accordingly. The data represent mean ± SE 
from three independent experiments.
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Figure 6. 
TNF-α and LPS inhibit thrombi-mediated nuclear translocation of p65 NF-κB in endothelial 
cells. HCAEC cells cultivated in an eight-well chamber slide were preconditioned for 14 h in 
the absence (A–C) or presence of TNF-α (D–F) or LPS (G–I). The preconditioning culture 
medium was then replaced with fresh medium in the absence (C, F, and I) or presence (B, 
E, and H) of thrombin for 2 h. The cells were fixed, washed, and incubated with monoclonal 
anti-p65 NF-κB antibody (green). Nuclei are stained by TO-PRO-3 (blue). Shown are the 
merged images; colocalization of p65 and nucleus causes bright blue color (B). NP; no 
preconditioning; NS, no thrombin stimulation; LPS, LPS preconditioning; TNF, TNF-α 
preconditioning; THR; thrombin stimulation. (Magnification ×60, bar=10 µm).
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Figure 7. 
A, B) Effect of preconditioning on inducible gene expression persists following removal of 
TNF-α from culture medium. A) Same as in Fig. 2 except that preconditioned HUVEC were 
replaced with fresh medium for 24 h before thrombin treatment. NS, no stimulation; THR, 
thrombin stimulation; NP, no preconditioning.
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Figure 8. 
Preconditioning with thrombin has little effect on LPS and TNF-α signaling in endothelial 
cells. A, B) HUVEC cells were serum starved for 6 h, preconditioned in the absence or 
presence of 1.5 U/ml thrombin for 14 h, and then treated with or without thrombin (1.5 U/
ml), TNF-α (20 ng/ml), or LPS (10 µg/ml). RNase protection assays were carried out as in 
Fig. 1.
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Table 1
Real-time PCR primer sequences
Gene Name Real-time PCR Primer (5' to 3')
Forward Reverse
CD44 CGGAGAGGCCAGCAAGTC ACTGGTCTGGAGTTTCTGACGAC
COX-2 CCTGGCGCTCAGCCATAC CCACACTCATACATACACCTCGGT
ICAM-1 CTCCAATGTGCCAGGCTTG CAGTGGGAAAGTGCCATCCT
PDGF-A CACAGCATCCGGGACCTC AGGCTGGTGTCCAAAGAATCC
E-Selectin TTCCGGGAAAGATCAACATGA CATTGAGCGTCCATCCTTCA
Tissue Factor CAACAGACACAGAGTGTGACCTCA AGGAGAAGACCCGTGCCAA
u-PA GGAAAACCTCATCCTACACAAGGA CGGATCTTCAGCAAGGCAAT
VCAM-1 TTCCCTAGAGATCCAGAAATCGAG CTTGCAGCTTACAGTGACAGAGC
β-Actin CCAGGATCAAGGTCGGAAAG GCATCGGACTTGCAGACCA
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